Dupilumab-Associated Cutaneous Adverse Events Among Adult Patients With Atopic Dermatitis: A Retrospective Study

    March 2023 in “ The Journal of Dermatology ”
    Maddalena Napolitano, Gabriella Fabbrocini, Cataldo Patruno
    Studysummary In this study, 16% of patients on dupilumab for atopic dermatitis experienced mild cutaneous adverse events, most commonly facial redness and psoriasis, leading to discontinuation in about 3% of cases.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 8

    1. Immunological Properties of Atopic Dermatitis-Associated Alopecia Areata International Journal of Molecular Sciences · 2021
    2. Early Onset of Alopecia Areata After Dupilumab Introduction in a Patient With Atopic Dermatitis European Journal of Dermatology · 2019
    3. Dupilumab And Alopecia: A Janus Effect Dermatologic Therapy · 2019
    4. Dupilumab Treatment for Atopic Dermatitis Leading to Unexpected Treatment for Alopecia Universalis JAAD case reports · 2019
    5. Dupilumab Improved Alopecia Areata in a Patient with Atopic Dermatitis: A Case Report Acta Dermato Venereologica · 2019
    6. Alopecia Areata in Severe Atopic Dermatitis Treated With Dupilumab Journal of Investigational Allergology and Clinical Immunology · 2018
    7. Drug-Induced Alopecia After Dupilumab Therapy JAAD case reports · 2018
    8. Alopecia Areata After Dupilumab for Atopic Dermatitis JAAD case reports · 2018